Advertisement
INCR vs RMTI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a StrongBuy and RMTI is a Buy.
INCR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for INCR turned positive on September 24, 2026. Looking at past instances where INCR's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INCR's RSI Oscillator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCR advanced for three days, in 150 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
INCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCR as a result. In 90 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for INCR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.140) is normal, around the industry mean (8.432). P/E Ratio (-2.993) is within average values for comparable stocks, (-1.821). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.640) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. INCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
RMTI in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
RMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where RMTI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMTI advanced for three days, in 195 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for RMTI moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 32 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RMTI as a result. In 59 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for RMTI turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
RMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RMTI crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RMTI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.788) is normal, around the industry mean (8.432). P/E Ratio (-5.197) is within average values for comparable stocks, (-1.821). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.435) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. RMTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
INCR | RMTI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 94 | |
PRICE GROWTH RATING 1..100 | 63 | 64 | |
P/E GROWTH RATING 1..100 | 32 | 52 | |
SEASONALITY SCORE 1..100 | n/a | 32 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMTI's Valuation (20) in the Medical Specialties industry is in the same range as INCR (21) in the Servicestothe Health Industry industry. This means that RMTI’s stock grew similarly to INCR’s over the last 12 months.
RMTI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that RMTI’s stock grew similarly to INCR’s over the last 12 months.
RMTI's SMR Rating (94) in the Medical Specialties industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that RMTI’s stock grew similarly to INCR’s over the last 12 months.
INCR's Price Growth Rating (63) in the Servicestothe Health Industry industry is in the same range as RMTI (64) in the Medical Specialties industry. This means that INCR’s stock grew similarly to RMTI’s over the last 12 months.
INCR's P/E Growth Rating (32) in the Servicestothe Health Industry industry is in the same range as RMTI (52) in the Medical Specialties industry. This means that INCR’s stock grew similarly to RMTI’s over the last 12 months.
| INCR | RMTI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 5 days ago 86% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| MACD ODDS (%) | 2 days ago 81% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 87% |
| Advances ODDS (%) | 26 days ago 69% | 29 days ago 82% |
| Declines ODDS (%) | 2 days ago 81% | 5 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCR’s FA Score shows that 2 FA rating(s) are green while RMTI’s FA Score has 1 green FA rating(s).
- INCR’s FA Score: 2 green, 3 red.
- RMTI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCR’s TA Score shows that 5 TA indicator(s) are bullish while RMTI’s TA Score has 3 bullish TA indicator(s).
- INCR’s TA Score: 5 bullish, 3 bearish.
- RMTI’s TA Score: 3 bullish, 7 bearish.
Price Growth
INCR (@Pharmaceuticals: Generic) experienced а -2.84% price change this week, while RMTI (@Pharmaceuticals: Generic) price change was -5.12% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.92%. For the same industry, the average monthly price growth was -10.60%, and the average quarterly price growth was +6.14%.
Reported Earning Dates
INCR is expected to report earnings on Nov 17, 2026.
RMTI is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.92% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement